2024 Financial Guidance
Management reiterates its full year 2024 guidance:
- Anticipated total DANYELZA net product revenues of between $95 million and $100 million;
- Anticipated operating expenses of between $115 million and $120 million;
- Anticipated total annual cash burn of between $15 million and $20 million; and
- Cash and cash equivalents anticipated to continue to support operations as currently planned into 2027.